natgillin/translations-raw huggingface dataset:
The term “bioactive metabolite” as employed herein refers to any functional group contained in a compound of formula I with an open valence for further substitution wherein such substitution can, upon biotransformation, generate a compound of formula I. Examples of such functional groups of bioactive metabolites include, but are not limited to, —OH, —NH or functional groups wherein the hydrogen can be replaced with a functional group such as —PO3H2 for example, which, upon biotransformation generates an —OH or —NH functional group of a compound of formula I. 
Termin "bioaktivni metabolit" kao što se ovdje upotrebljava, odnosi se na bilo koju funkcionalnu skupinu koja sadrži spoj formule I sa otvorenom valencijom za daljnju supstituciju gdje takva supstitucija može, nakon biotransformacije, davati spoj formule I. Primjeri takvih funkcionalnih skupina bioaktivnih metabolita uključuju, ali bez ograničenja, -OH, -NH ili funkcionalne skupine gdje se vodik može zamijeniti sa funkcionalnim skupinama kao što su -PO3;H>, npr., koji nakon biotransformacije daje -OH ili -NH funkcionalnu skupinu spoja formule I.
The method of claim 1, wherein the antibody is a monoclonal antibody. 
Postupak prema patentnim zahtjevima od 1 do 27, naznačen time, da je protutijelo monoklonsko protutijelo.
It is also preferred that the flow body projects over the leading edge or the trailing edge by maximally 10%, preferably by maximally 7%, particularly preferably by maximally 5% of the mean profile length of the rudder blade. It is thus achieved that the flow body has only a slight projection with respect to the rudder blade and thus does not influence negatively the propulsion behavior like a Costa bulb. 
Kormilo u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što je maksimalno izbočenje tijela oko kojega prolazi strujanje (41) preko čeonog ruba (11, 21) i/ili preko stražnjeg ruba (30) 10 %, poželjno 7 %, naročito poželjno 5 % od srednje duljine profila lopatice kormila (100).
A compound of Formula (I) wherein D is N, CH, or CF; 
Spoj Formule (I), naznačen time što D je N, CH ili CF;
• R1 is selected from a C10-C22-alkenyl with 3-6 methylene interrupted double bonds in Z configuration, and a C10-C22 alkynyl having 1-6 triple bonds; 
* R; je odabran od Ci9-C22-alkenila s 3-6 metilenskih prekinutih dvostrukih veza u Z konfiguraciji, i -C2> alkinil koji ima 1-6 trostrukih veza;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
continuously determining the movement performed by the movement of the hand of the user and establishing a turning angle (a), 
rotacija vrši pokretima ruke korisnika (1) te se kao i zakretni kut (a) stalno određuje, -
System for treating water at low cost, according to claim 1, wherein the filtration means comprises cartridge filters, sand filters, micro-filters, ultra-filters, nano-filters, or a combination thereof. 
Uređaj za obradu vode uz nizak trošak, prema bilo kojem prethodnom zahtjevu, naznačen time što sredstva za filtriranje (3) sadrže filterske uloške, pješčane filtre, mikro-filtre, ultra-filtre, nano-filtre, ili njihovu kombinaciju.
The oil was chromatographed on silica gel, using an ethyl acetate/hexane/diethylamine (16/16/0.3) solvent mixture for elution, to separate the cis- and trans-isomers. 
Ulje se kromatografira na silika-gelu korištenjem etilacetat/heksan/dietilaminske (16/16/0.3) topive smjese za eluiranje, tako da se odvoje cis-i trans-izomeri.
purifying memory B cells which do not express IgM from the sample in which the antibody which binds to said specimen but not to tissue without said pathological structures is present; 
(b) utvrđivanje prisutnosti protutijela u uzorku koja se vežu na navedeni uzorak, ali ne na odgovarajuće tkivo zdravih osoba bez takvih patoloških struktura;
Isolated polynucleotide comprising a polynucleotide of SEQ ID NO:5 and a polynucleotide of SEQ ID NO:6. 
Izolirani polinukleotid, naznačen time, da obuhvaća polinukleotid od SEQ ID NO:5 1 polinukleotid od SEQ ID NO:6.
In accordance with a first aspect of the present invention, there is provided a delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at about pH 5 or above, and wherein the inner layer comprises a third polymeric material that is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said third polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base. 
HR P20180068 T1 PATENTNI ZAHTJEVI Formulacije lijeka s produljenim oslobađanjem za oralnu primjenu za isporuku lijeka u debelo crijevo pacijenta, pri čemu spomenuta formulacija sadrži jezgro, to jezgro sadrži lijek i prevlaku za jezgru, jezgru koja sadrži lijek i ovojnicu koja sadrži vanjski i unutarnji sloj, pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima graničnu vrijednost pH na pH 6,5 ili više, 1 pri čemu unutarnji sloj sadrži treći polimerni materijal koji je topiv u crijevnoj tekućini, spomenuti treći polimerni materijal je polimer polikarboksilne kiseline koji je bar djelomično neutraliziran, pri čemu bar 10% skupina karboksilne kiseline polimera polikarboksilne kiseline su u obliku aniona karboksilata.
Methanol was removed in vacuo. 
Metanol je uklonjen in vacuo.
a binding domain capable of binding to the extracellular domain of the mutated human FAPa chimera having an amino acid sequence as depicted in SEQ ID NO: 448, wherein the amino acid residues at positions 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 and 362 are mutated to the corresponding amino acid residues of the wt rodent FAPa, but not to the extracellular domain of the rodent FAPa; 
(b) vežuća domena, koja se može vezati na izvanstaničnu domenu kimere mutiranog ljudskog FAPa s aminokiselinskim slijedom kao što je opisan u SEQ ID NO: 448, gdje su aminokiselinski ostaci na položajima 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 1 362 mutirani u odgovarajuće aminokiselinske ostatke FAPa divljeg tipa glodavca, no ne i na izvanstaničnu domenu FAPa divljeg tipa;
Method for treating water at low cost, according to claim 2, wherein the Langelier Saturation Index or Stiff & Davis Saturation index is kept under 2 by a process selected from pH adjustment, the addition of antiscalants, or a water softening process. 
Metoda niskih troškova za tretiranje vode, u skladu s patentnim zahtjevom 2, pri čemu se Langelierov indeks zasićenja ili Stiffov i Davisov indeks zasićenja drže ispod 2 postupkom odabranim između namještanja pH, dodavanja sredstva protiv kamenca, ili postupkom omekšavanja vode.
The vaccine or peptide for use according to claim 11, wherein the further cancer treatment is selected from the group consisting of chemotherapy, radiotherapy, treatment with immunostimulating substances, gene therapy, treatment with antibodies and treatment using dendritic cells. 
Cjepivo ili peptid za primjenu prema zahtjevu 11, naznačeno time, stoje dodatna terapija protiv raka odabrana iz grupe koja se sastoji od kemoterapije, radioterapije, liječenja imunostimulirajućim = sredstvima, = genske terapije, = liječenja antitijelima 1 liječenja pomoću dendritičkih stanica.
hypertension before, during, or after surgery, 
(d) hipertenzija prije, za vrijeme, ili nakon operacije,
These results indicate that the presence of starch in the outer layer enables release of a significant amount of the active when exposed to colonic enzymes even though the pH of the surrounding medium is well below the pH threshold of the second polymeric material. 
Formulacija lijeka s odloženim otpuštanjem sukladno u jednom od prethodnih patentnih zahtjeva, naznačeno time, da su prvi i drugi polimerni materijali prisutni u vanjskom sloju u odnosu od najviše 60:40.
A flavour enhancer such as glucono-δ-lacton can be added to the sweetener composition. 
Sastavini zaslađivača može se dodati pojačivač okusa, npr. glukono-5-lakton.
A combination according to claim 4 wherein the antiinfective agent is an antibiotic or antiviral. 
Kombinacija u skladu s patentnim zahtjevom 4, naznačen time što je antiinfektivno sredstvo antibiotik ili antivirusno sredstvo.
or a pharmacologically acceptable salt thereof. 
ili njegova farmakološki prihvatljiva sol.
Vessel according to claim 1, wherein said electric motor is arranged to increase and to reduce a moving speed of said weight. 
Plovilo (200, 300, 400, 600) sukladno zahtjevu 6 ili 7, pri čemu je električni motor (568a, b) organiziran da poveća i reducira brzinu pomicanja utega (452, 552, 652).
W is a group of formula (Wb) as defined in Claim 2; 
W je skupina formule (W,) definirana kao u zahtjevu 2;
The method of claim 13, wherein the suitable salt formed is a hydrogen fumarate salt of Compound I. 
. Postupak prema zahtjevu 29, gdje je dobivena sol vodik fumarat sol Spoja I.
reacting said bromo compound obtained in Step (b) with a compound of formula: to yield the compound of formula: 
[image], reakcije navedenog bromiranog spoja dobivenog u koraku (b) sa spojem formule:
receiving (1102) a multimedia broadcast multicast service MBMS service (940) from a first cell (912) in a first multicast broadcast single frequency network MBSFN area (910) while in a radio resource control RRC idle mode; 
primitak (1102) MBMS servisa (940) od prve stanice (912) u prvom MBSFN području (910) dok je RRC neaktivnom režimu;
The method of claim 10, wherein the reference resource set is determined based on the resource set used for transmitting the control message. 
Metoda iz patentnog zahtjeva 10, gdje je referentni skup resursa određen od skupa resursa koji je korišten za prijenos kontrolne poruke.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the composition comprises at least about 80 % (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da pripravak sadrži najmanje oko 80 % (težinski) polietilen oksida koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000.
The noradrenaline injectable solution has a surprising stability, even at high temperatures. 
POSTUPAK ZA PROIZVODNJU STABILNE, INJEKTABILNE OTOPINE NORADRENALINA NISKE KONCENTRACIJE
A compound of formula IIa: wherein R2 is H or cyclopropyl; 
Spoj formule IIa: [image] gdje je H ili ciklopropil;
R9a and R9b are independently selected from the group consisting of H; 
a i R9b se neovisno bira iz skupine koju čine H;
A method of producing a compound of formula [1a] comprising a step of reacting a thiazole derivative of formula [2] and a benzene derivative of formula [3] under a presence of an acid or Lewis acid and a solvent: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 R10, G1, X1, X2 X3, X4 T and n are as defined in Claim 1. 
Postupak za proizvodnju spoja formule [1a] naznačen time što obuhvaća korak reakcije tiazolnog derivata formule [2] i benzenskog derivata formule [3] u prisutnosti kiseline ili Lewisove kiseline i otapala: pri čemu R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, G1, X1, X2, X3, X4, T i n su kako je definirano u zahtjevu 1.
The antibody of any of claims 1-7, wherein the antibody is a chimeric or single chain antibody. 
Protutijelo iz bilo kojeg od patentnih zahtjeva 1-2, pri čemu je protutijelo kimerno ili jednolančano protutijelo.
Thus, the piercer 11 of this fourth embodiment is a simple single-use piercer that cannot close the outlet of the container 2 once the closure 22 has been pierced. 
Tako, dakle, bušilo 11 u ovoj četvrtoj izvedbi je jednostavno bušilo za jednokratnu upotrebu, koje ne može zatvoriti izlaz iz spremnika 2 kad se probuši poklopac 22.
The device according to claim 1, further comprising a user-operated switching device, wherein an electrical connection of a power source to the first and second electrodes is enabled by the switching device, wherein the switching device is disposed on a main board, and wherein the charging circuit is disposed on the main board. 
Uređaj prema zahtjevu 6, naznačeno time da uređaj ima sklopni uređaj kojime upravlja korisnik, koji omogućuje električno povezivanje izvora napajanja i elektroda (3, 7) i koji se nalazi na glavnoj ploči unutar uređaja, te da se strujni krug punjenja nalazi na glavnoj ploči.
amino acid sequence of the a-chain of human FSH 
Broj objave europskog patenta:
The method as claimed in claim 7 wherein data points in the driver profile are, for at least one profile index, classified against a plurality of possible values for the profile index, and wherein deriving the analysis profile comprises merging two or more possible values of the profile index. 
Postupak prema zahtjevima 8 ili 9, naznačen time da su podatkovne točke u vozačevom profilu, barem u jednom indeksiranom profilu, određene u odnosu na mnoštvo mogućih vrijednosti od indeksiranog profila i pri čemu deriviranje analitičkog profila sadrži spajanje dvije ili više moguće vrijednosti indeksiranog profila.
The method of claim 2, wherein the at least one allele has been inactivated using a Cre-lox recombination system. 
Svinja iz bilo kojeg zahtjeva 1-5, pri čemu je barem jedan alel deaktiviran pomoću Cre-lox rekombinacijskog sustava.
A combination according to claim 5 wherein the B2 agonist is salmeterol xinafoate. 
Kombinacija sukladno patentnom zahtjevu 5, naznačena time, da je f2 agonist salmeterol ksinafoat.
The humanized anti-human a9 integrin antibody according to claim 2, wherein the heavy chain variable region consists of the amino acid sequence shown by SEQ ID NO: 1 or SEQ ID NO: 31, having 
varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:15 i varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:9;
Drying of the salt is performed at a temperature of 25-30° C. 
Sušenje soli provodi se pri temperaturi od 35-30 *C.
deprotection of the amine group of hexamethylenediamine; 
Datum podnošenja europske prijave patenta:
The spacer may comprise a spacer for supporting one edge of the translucent panel. 
Sustav prema zahtjevu 9, pri čemu distantno sredstvo sadrži distancer (65) za oslanjanje jednog brida zidnog panela.
A transgenic plant comprising the host cell of claim 7 . The plant of claim 8, wherein said plant is selected from the group consisting of maize, sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, and oilseed rape. 
Transgenička biljka koja sadrži biljnu stanicu domaćina iz patentnog zahtjeva 5, naznačena time, da je navedena biljka poželjno odabrana iz skupine koja se sastoji od kukuruza, sirka, pšenice, suncokreta, rajčice, zeljarica, paprika, krumpira, pamuka, riže, soje, šećerne repe, šećerne trske, duhana, ječma i uljane repice.
The IL-17 binding antibody or fragment thereof of claim 10, wherein said IL-17 binding antibody or active fragment thereof is co-administered, concomitantly or in sequence, with at least one second drug substance selected from the group consisting of immunosuppressive agents, immunomodulatory agents, anti-inflammatory agents, chemotherapeutic agents or anti-infectious agents. 
IL-17 vežuće antitijelo ili njegov fragment za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu spomenuto IL-17 vežuće antitijelo ili njegov fragment trebaju biti primjenjivani u kombinaciji, simultano ili odvojeno, s najmanje jednom sekundarnom ljekovitom supstancom izabranu iz skupine koja se sastoji od imunosupresivnih agensa, imunomodulatornih agensa, protuupalnih agensa, kemoterapeutskih agensa ili protuinfektivnih agensa.
The Polypeptide Mixture of the Invention: EAE 
Datum podnošenja europske prijave patenta:
Composition as defined in claims 8 to 12 being administered, orally, topically, by inhalation, by suppository, intravenously, subcutaneously or intramuscularly. 
Sastav za upotrebu temeljem zahtjeva 1, pri čemu se sastav daje, oralno, topikalno, inhalacijom, supozitorijem, intravenozno, potkožno ili intramuskularno.
fixed each time to the preceding pairs (2, 2',...) of half shells (1, 1'), which were already previously fixed to each other, of the panel (49, 49') being formed, until the final desired length of the panel is reached (8). 
fiksira svaki put na prethodne parove (2, 2',...) polu-okvira (1, 1'), koji su već HR P20131152 TI prethodno bili međusobno fiksirani, na panel (49, 49') koji se formira, sve dok se ne postigne konačna željena duljina panela (8).
hydrogen, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, hydroxy, lower alkoxy, carboxy, lower alcoxycarbonyl, acyl, nitro, carbamoyl, lower alkylaminocarbonyl, —NR5R6, wherein R5 and R6 are each independently selected from hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted lower alkylaminocarbonyl, substituted or unsubstituted lower arylaminocarbonyl, alkoxycarbonyl, carbamoyl, acyl or R5 and R6 are combined with a nitrogen atom from a heterocyclic group, 
(a) vodik, halogen, supstituirani ili nesupstituirani niži alkil, supstituirani ili nesupstituirani niži alkenil, supstituirani ili nesupstituirani niži alkinil, hidroksi, niži alkoksi, karboksi, niži alkoksikarbonil, acil, nitro, karbamoil, niži alkilaminokarbonil, -NRŽR", gdje su svaki R? i R" nezavisno izabrani od vodika, supstituiranog ili nesupstituiranog nižeg alkila, supstituiranog ili nesupstituiranog nižeg alkenila, supstituiranog ili nesupstituiranog nižeg alkinila, supstituiranog ili nesupstituiranog arila, supstituiranog ili nesupstituiranog heteroarila, supstituiranog ili nesupstituiranog aralkila, supstituiranog ili "nesupstituiranog nižeg alkilaminokarbonila, supstituiranog ili nesupstituiranog nižeg arilaminokarbonila, -alkoksikarbonila, karbamoila, acila ili R? i R" su spojeni sa atomom dušika iz heterociklične grupe,
The domain antibody (dAb) according to any one of claims 1-12 for the use according to claim 14, wherein the patient has or is at risk of having an autoimmune disease or a graft-related disease, preferably a disease selected from the group consisting of an allograft rejection, a xenograft transplant rejection, graft versus host disease, systemic lupus erythematosis, multiple sclerosis, rheumatoid arthritis, diabetes, psoriasis, scleroderma, atherosclerosis, inflammatory bowel disease, and ulcertative colitis. 
Antitijelo sa jednim imunoglobulinskim varijabilnim domenom prema bilo kojem od patentnih zahtjeva 1-11 za primjenu u metodi liječenja, ublažavanja ili sprečavanja autoimune bolesti ili bolesti u vezi sa kalemom, poželjno bolesti odabrane iz grupe koja se sastoji od odbacivanja alografta, odbacivanja transplantata ksenografta, bolesti presatka protiv domaćina, sistemskog eritematoznog lupusa, Sjogrenovog sindroma, multiple skleroze, reumatoidnog artritisa, dijabetesa, psorijaze, skleroderme, ateroskleroze, upalne bolesti crijeva, Kronove bolesti, ulceroznog kolitisa, i lupus nefritisa.
Some representative examples the statin compounds include rosuvastatin, pravastatin and its sodium salt, simvastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin, pitavastatin, BMS's “superstatin”, and HMG-CoA reductase inhibitors known in the art. 
Neki tipični primjeri statinskih spojeva uključuju rosuvastatin, pravastatin i njegovu natrijevu sol, simvastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin, pitavastatin, BMS' "superstatin", te inhibitore HMG-Co reduktaze poznate u struci.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™ 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema bilo kojem zahtjevu od 1 do 5, naznačen time da je aktivni agens oksikodon hidroklorid i da je oblik davanja kada je testiran u usporednoj kliničkoj studiji je bioekvivalentan komercijalnom proizvodu OxyContinTM.
A composition according to claim 1 comprising 0.4 w/v% carbomer, 0.2 w/v% guar, 0.5 w/v% boric acid, and 0.3 w/v% nepafenac. 
Sastav prema zahtjevu 11, naznačen time, da obuhvaća 0,4 % (masa/volumen) karbomera, 0,2 % (masa/volumen) guara, 0,5 % (masa/volumen) borne kiseline, i 0,3 % (masa/volumen) nepafenaka.
Contacting the biological fluid or cell extract with the HCIC, could be carried out at the pH of the crude harvest or neutral PH or alternatively prior to contacting, the pH of the column and the crude harvest could be adjusted to acidic pH e.g. 
Dovođenje u kontakt biološke tekućine ili staničnog ekstrakta sa smolom za HCIC može se provesti pri pH vrijednosti koju ima sirovi prikupljeni materijal ili pri neutralnom pH ili alternativno, prije dovođenja u kontakt se pH kolone i sirovog materijala može podesiti na kiseli pH, npr.
An apparatus for mining and processing seabed sediment comprising a crawler mining tool configured to travel across the seabed and form a slurry; a production riser configured to transport the slurry from the crawler to the surface; a first separator configured to dissociate hydrates and remove hydrates from the slurry in gaseous form at the surface; and means to transport the slurry or components of the degasified slurry to an on-shore location. 
Uređaj za miniranje i obradu taloga morskog dna obuhvaća gusjenični alat za miniranje (2) za putovanje morskim dnom (3) i stvaranje mulja; proizvodne uzlazne cijevi (6) za transport mulja od gusjeničara (2) do površine; prvi razdjelnik za odvajanje hidrata i uklanjanje hidrata iz mulja u plinovitom obliku na površinu; karakteriziran sredstvom transporta mulja na mjesto na obali.
A pharmaceutical composition comprising the peptide mixture of any of clauses 1 to 10, a peptide for use according to clause 11, a peptide according to clause 12 or the T-cell mixture or T-cell preparation of clause 13 and a pharmaceutically acceptable carrier, diluent and/or excipient. 
Farmaceutska kompozicija koja sadrži peptidnu smjesu iz bilo kojeg od patentnih zahtjeva 1-3, ili smjesu T stanica iz patentnog zahtjeva 4 1 farmaceutski prihvatljiv nosač, razblaživač i/ili ekscipijens.
The pharmaceutically acceptable transdermal composition of claim 10, wherein the active agent is entacapone, or a pharmaceutically acceptable salt thereof. 
Farmaceutski prihvatljiv transdermalni sastav iz zahtjeva 10, naznačeno time da je aktivni sastojak entakapon ili farmaceutski prihvatljiva sol istog.
1 . A crystalline form according to claim 1 characterized by a differential scanning calorimetry curve to have an onset of melting which is comprised in the range 163-174° C. 
Kristalna forma, prema nekom od prethodnih zahtjeva, naznačena time što krivulja diferencijalne skenirajuće kalorimetrije ima početak topljenja u opsegu 163-174*C.